Intelligent Bio Solutions Inc.

What they do

The company sells the Intelligent Fingerprinting Drug Screening System (IFP System), a two-part portable device that analyzes fingerprint sweat for drugs of abuse, including opiates, cocaine, methamphetamines, benzodiazepines, cannabis, methadone, and buprenorphine. It is commercially available in certain countries outside the U.S. and targets safety-critical industries such as construction, transportation, mining, manufacturing, and drug treatment. The company also holds a license for a biosensor platform, but development is on hold due to the licensor's liquidation.

Revenue drivers

• IFP System sales in UK and Europe — Primary revenue source, with customers in safety-critical industries and drug rehabilitation; growth is driven by increasing market share in the UK and mainland Europe.
• APAC expansion — Planned entry into Australia, New Zealand, and other APAC markets; currently establishing infrastructure and regulatory compliance.
• U.S. market entry — FDA 510(k) pre-market notification submitted in December 2024; initial launch planned for an opiate test for codeine, pending clearance.
• New customer segments — Expanding beyond current segments to include sporting organizations, law enforcement, and commercial airlines.

Recent performance

For fiscal 2025 (year ended June 30, 2025), revenue was $3.1M, flat versus fiscal 2024, with a net loss of $10.6M. Operating cash flow was -$9.7M. In the quarter ended March 31, 2026, revenue was $1.1M, up from $896,774 in the prior quarter. Total assets were $14.9M, cash and equivalents $6.9M, and shareholder equity $9.0M as of March 31, 2026.

Strategy

The company plans to grow market share in the UK and Europe, commence distribution in APAC, and seek FDA clearance for U.S. sales. It also aims to expand the IFP System's drug panel and enter point-of-care medical testing. Management is developing a distributor network across APAC, Europe, and North America and pursuing new customer segments. The biosensor platform's future is uncertain pending the completion of the licensor's liquidation.

Risks

• Going concern — The independent auditor included an explanatory paragraph on the ability to continue as a going concern in the fiscal 2025 financial statements.
• Need for additional capital — The company has incurred significant losses since inception and will need to raise additional capital; if unsuccessful, it may be forced to sell assets or cease operations.
• Single-source suppliers — The company depends on a limited number of single-source suppliers for certain IFP System components, making it vulnerable to supply shortages and price fluctuations.
• Biosensor platform uncertainty — Development of the biosensor platform is stalled because the University of Newcastle cannot finalize licensing until the liquidation of LSBD is complete, with an unknown timeline.
• Foreign exchange exposure — Results may be impacted by changes in foreign currency exchange rates, given the company's global operations.

Outlook

Management expects to grow in existing markets and enter new ones, with a focus on the UK, Europe, and APAC. FDA clearance is a key near-term milestone for U.S. expansion, with an initial opiate test for codeine planned. The company acknowledges the risk of not achieving significant revenues or profitability and continues to face capital needs.